| Summary of Accrued Expenses |
The following table summarizes the Company’s accrued expenses for each of the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
As of
June 30, 2026 |
|
|
As of
December 31, 2025 |
|
|
|
(in thousands) |
|
Product revenue related reserves |
|
$ |
118,639 |
|
|
$ |
117,518 |
|
Accrued contract manufacturing costs |
|
|
41,256 |
|
|
|
92,281 |
|
Accrued employee compensation costs |
|
|
40,972 |
|
|
|
58,607 |
|
Accrued litigation contingency charge |
|
|
39,000 |
|
|
|
— |
|
Accrued professional fees |
|
|
20,874 |
|
|
|
17,840 |
|
Accrued interest expense |
|
|
15,847 |
|
|
|
20,714 |
|
Accrued clinical and pre-clinical costs |
|
|
15,308 |
|
|
|
18,894 |
|
Accrued royalties |
|
|
10,200 |
|
|
|
10,863 |
|
Accrued income taxes |
|
|
9,309 |
|
|
|
4,755 |
|
Accrued clinical collaboration costs |
|
|
5,155 |
|
|
|
10,222 |
|
Accrued milestone costs |
|
|
3,200 |
|
|
|
1,000 |
|
Other |
|
|
5,472 |
|
|
|
6,965 |
|
Total accrued expenses |
|
$ |
325,232 |
|
|
$ |
359,659 |
|
|